{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:46:44Z","timestamp":1790275604521,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ctrv.2017.08.009","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T03:00:32Z","timestamp":1503543632000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review"],"prefix":"10.1016","volume":"60","author":[{"given":"Markus V.","family":"Heppt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Steeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Gabriel","family":"Schlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Rosumeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.08.009_b0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ejca.2011.10.004","article-title":"Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe","volume":"48","author":"Mallone","year":"2012","journal-title":"Eur J Cancer"},{"issue":"536\u201343","key":"10.1016\/j.ctrv.2017.08.009_b0010","first-page":"e2","article-title":"The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis","volume":"116","author":"Weis","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ctrv.2017.08.009_b0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.009_b0020","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.28480","article-title":"Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options","volume":"120","author":"Agarwala","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.08.009_b0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0040","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.009_b0050","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.009_b0055","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.009_b0060","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0065","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2017.08.009_b0070","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2017.08.009_b0075","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial","volume":"32","author":"Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0080","first-page":"894","article-title":"Clinical efficacy of the anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibody ipilimumab in pretreated metastatic uveal melanoma patients","volume":"33","author":"Danielli","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2017.08.009_b0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1359-6349(09)71959-7","article-title":"Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy","volume":"7","author":"Danielli","year":"2009","journal-title":"EJC supplements"},{"key":"10.1016\/j.ctrv.2017.08.009_b0090","doi-asserted-by":"crossref","unstructured":"Rullan Iriarte AJ, Martin-Algarra S, De La Cruz Merino L, Rodriguez Abreu D, Espinosa E, Berrocal A et al. Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14\u201302. Ann Oncol 2016;27.","DOI":"10.1093\/annonc\/mdw378.54"},{"key":"10.1016\/j.ctrv.2017.08.009_b0095","article-title":"Trial in progress: clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401","volume":"26","author":"Dummer","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9554","article-title":"The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM)","volume":"35","author":"Patel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9533","article-title":"Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962","volume":"35","author":"Piulats","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0110","first-page":"3344","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2017.08.009_b0115","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CMR.0000000000000343","article-title":"A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy","volume":"27","author":"Itchins","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9588","article-title":"Activity of anti-PDI drugs in uveal melanoma patients","volume":"34","author":"Piperno-Neumann","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e21042","article-title":"PD-1 blockade to treat mucosal and uveal melanoma: the University of Pittsburghh experience","volume":"34","author":"Tian","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/0284186X.2016.1260773","article-title":"Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands","volume":"56","author":"van der Kooij","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0135","doi-asserted-by":"crossref","first-page":"e1143997","DOI":"10.1080\/2162402X.2016.1143997","article-title":"Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma","volume":"5","author":"Karydis","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2017.08.009_b0140","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.08.009_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9574","article-title":"Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts","volume":"35","author":"McKean","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0150","article-title":"A single center experience in heavily pretreated melanoma patients in an ipilimumab expanded access programme at the klaipeda university hospital (lithuania)","volume":"11","author":"Cesas","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ctrv.2017.08.009_b0155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2017.08.009_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1","volume":"34","author":"Naing","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0165","doi-asserted-by":"crossref","unstructured":"Schmerling R, Herchenhorn D, Rinck JA, De Camargo VP, Camargo J, Serrano SV et al. Ipilimumab for stage unresectable III\/IV melanoma: Brazilian experience in an expanded access program. J Clin Oncol 2014;32.","DOI":"10.1200\/jco.2014.32.15_suppl.e20045"},{"key":"10.1016\/j.ctrv.2017.08.009_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.9031","article-title":"Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups","volume":"32","author":"Zimmer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/IIO.0000000000000148","article-title":"Immunotherapy for uveal melanoma","volume":"57","author":"Breazzano","year":"2017","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ctrv.2017.08.009_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e20039","article-title":"Ipilimumab for advanced, refractory melanoma: a report of the Israeli cohort of expanded access program","volume":"31","author":"Shapira-Frommer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0185","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0959-8049(16)30320-3","article-title":"Combined radiofrequency ablation (RFA) and ipilimumab (IPI) in uveal melanoma: phase 1b results from the SECIRA-UM trial","volume":"51","author":"Blank","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.08.009_b0190","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","article-title":"Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)","volume":"52","author":"Kelderman","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0195","doi-asserted-by":"crossref","unstructured":"Maio M, Chairion Sileni V, Pilla L, Nicoletti SVL, Di Guardo L, Queirolo P et al. Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: Experience from Italian clinics participating in the European expanded access programme (EAP). Ann Oncol 2012;23:ix369\u2013ix70.","DOI":"10.1016\/S0923-7534(20)33688-7"},{"key":"10.1016\/j.ctrv.2017.08.009_b0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0923-7534(20)33704-2","article-title":"Ipilimumab for advanced melanoma in an expanded access programme (EAP): ocular, mucosal and acral subtype UK experience","volume":"23","author":"Shaw","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4143\/crt.2016.024","article-title":"Ipilimumab real-world efficacy and safety in korean melanoma patients from the korean named-patient program cohort","volume":"49","author":"Jung","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.08.009_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2017.08.009_b0215","first-page":"1219","article-title":"Phase II study evaluating Ipilimumab monotherapy in the first-line treatment of adult patients with metastatic uveal melanoma (MUM): the GEM1 trial","volume":"27","author":"Piulats","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"Danielli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2017.08.009_b0225","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0230","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma","volume":"26","author":"Kottschade","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0235","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9524","article-title":"Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172)","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9554","article-title":"Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)","volume":"34","author":"Shoushtari","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0245","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-016-1856-z","article-title":"Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis","volume":"65","author":"Heppt","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2017.08.009_b0250","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2017.08.009_b0255","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","article-title":"Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma","volume":"4","author":"Theurich","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2017.08.009_b0260","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00432-016-2318-x","article-title":"Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma","volume":"143","author":"Atkinson","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0265","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-017-0606-5","article-title":"Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies","volume":"19","author":"Komatsubara","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2017.08.009_b0275","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(17)30254-1","article-title":"Adopting a new stance on immunotherapy for uveal melanoma","volume":"18","author":"Komatsubara","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.009_b0280","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/atm.2016.05.04","article-title":"Uveal melanoma as a target for immune-therapy","volume":"4","author":"Oliva","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2017.08.009_b0285","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.08.009_b0290","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/pcmr.12304","article-title":"Biology of advanced uveal melanoma and next steps for clinical therapeutics","volume":"28","author":"Luke","year":"2015","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:34:07Z","timestamp":1602808447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217301329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":58,"alternative-id":["S0305737217301329"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.08.009","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}